Perception of self: distinguishing autoimmunity from autoinflammation

Abstract

Rheumatic diseases can be divided in two groups, autoinflammatory and autoimmune disorders. The clinical presentation of both types of diseases overlap, but the pathological pathways underlying rheumatic autoinflammation and autoimmunity are distinct and are the subject of ongoing research. There are a number of ways in which these groups of diseases differ in terms of disease mechanisms and therapeutic responses. First, autoinflammatory diseases are driven by endogenous danger signals, metabolic mediators and cytokines, whereas autoimmunity involves the activation of T and B cells, the latter requiring V-(D)-J recombination of receptor-chain gene segments for maturation. Second, the efficacy of biologic agents directed against proinflammatory cytokines (for example IL-1β and TNF) also highlights differences between autoinflammatory and autoimmune processes. Finally, whereas autoinflammatory diseases are mostly driven by inflammasome-induced IL-1β and IL-18 production, autoimmune diseases are associated with type I interferon (IFN) signatures in blood. In this Review, we provide an overview of the monocyte intracellular pathways that drive autoinflammation and autoimmunity. We convey recent findings on how the type I IFN pathway can modulate IL-1β signalling (and vice versa), and discuss why IL-1β-mediated autoinflammatory diseases do not perpetuate into autoimmunity. The origins of intracellular autoantigens in autoimmune disorders are also discussed. Finally, we suggest how new mechanistic knowledge of autoinflammatory and autoimmune diseases might help improve treatment strategies to benefit patient care.

Autoimmunity in uveitis

“…As diverse autoantibodies (e.g. Recent classification of inflammatory diseases into autoimmune, mixed and auto-inflammatory diseases takes these differences into account (McGonagle & McDermott 2006;Kastner et al 2010;Abramovits & Oquendo 2013;Davila-Seijo et al 2014;van Kempen et al 2015;Pathak et al 2017). Self-directed inflammation by autoinflammatory diseases is caused by an overactivity of the adaptive and/or innate immune system, without specific identification of autoreactive B-and Tcell responses (e.g.…”

Extracellular nucleosides and nucleotides as immunomodulators

“…Its role in ICD depends on the TLR4 MyD88 signaling route and the subsequent release of interleukin (IL)‐1β by activated DC (Figure ) . However, neither PAMP nor DAMP are able to trigger adaptive immunity alone unless antigenic neo‐epitopes from either microbial or oncogenic origin, which have not provoked central or peripheral tolerance earlier, are present …”

Update on rheumatic heart disease

“…Rheumatic disorders can be divided into primarily autoimmune and autoinflammatory, with some overlap, but each having distinct mechanisms [11]. Autoinflammatory disorders are primarily of the innate immune response and driven by inflammasome-induced IL(interleukin)-1b and IL-18 [12].…”